samedan logo

home > news > detailed info

3P Biopharmaceuticals appoints José Luis Bartolomé as Operational Excellence Director

3P Biopharmaceuticals

Professional with extensive experience in biotechnology companies

[Noáin, Spain, September 30, 2020]3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, appoints a new member to the management team with the incorporation of José Luis Bartolomé as Operational Excellence and Continuous Improvement Director.

José Luis Bartolomé has a solid profile in equipment and operations management and joins 3P Biopharmaceuticals with the aim of improving the company's internal processes.

José Luis comes to 3P with more than 30 years of experience in the biotechnology sector. He has a degree in biology from Santiago de Compostela University and throughout his extensive experience has worked in different biotechnology companies.

His professional career began in 1986 at Cooper Zeltia, and later he worked in the production department of companies such as Wellcome-Biofarma, Glaxo, Genentech and Lonza, in all of which he was a Production Manager. Before joining the 3P team, he was General Manager at Laboratorios Ovejero.

Therefore, his professional career has been developed in GMP environments, and he is an expert in the implementation of technology transfers, as well as working in facilities and processes subject to continuous customer audits or by different regulatory authorities (FDA, AEMPS, etc.)

“I appreciate the confidence 3P has shown me by giving me the opportunity to work with such a highly qualified team. I hope to contribute my experience in leading biotechnology companies to achieve excellence through continuous improvement”, explained Bartolomé.

Dámaso Molero, CEO at 3P Biopharmaceuticals said:"it is a pleasure to welcome José Luis to 3P and to incorporate such an experienced profile into our management team. I am sure that his arrival will give a boost to 3P in many aspects”.

“With my previous experience I hope to help analyze situations and processes that can be modified for our clients greater satisfaction and confidence, as well as strengthen 3P to optimize employee development and their professional growth”, added Bartolomé.

Therefore, with this new addition to the management team,3P Biopharmaceuticals continues its growth plan and consolidates a competitive position as one of the leading CDMOs in Europe.

About 3P Biopharmaceuticals
3P Biopharmaceuticals is a leading CDMO specialized in process development and GMP manufacturing of biologics and cell therapy products. 3P offers solutions at all stages of biologics development, from the initial process and analytics development to preclinical and clinical phases and commercial production. Its extensive experience, flexibility, and adaptation, as well as its innovative technology and qualified team, have made 3P an example for the international market. For further information: 

3P Biopharmaceuticals contact:
Isabel García
Communications & Marketing at 3P Biopharmaceuticals
Phone: + 34 948 346 480
phone +34 948 34 64 80
email Polígono Mocholí, C/ Mocholí 2, 31110 Noáin, Navarra, Spain
Print this page
Send to a friend
News and Press Releases


The National Institute for Clinical and Health Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) have recognised the potential of Shionogi’s innovative antibiotic, cefiderocol, and selected it for inclusion in this pilot reimbursement model which ‘de-links’ payment from volume of use Shionogi recognises the UK’s leadership role in introducing this first fully ‘delinked’ pilot reimbursement model, which is an important step in making the market for novel antibiotics more predictable and sustainable; we strongly believe in the introduction of further suitable pull incentives in order to help stimulate the antimicrobial development pipeline Fetcroja® (cefiderocol) is indicated for the treatment of infections due to aerobic Gram-negative bacteria in adults with limited treatment options1 Antimicrobial resistance (AMR) is a major health burden which results in over 700,000 deaths globally2 and 5,000 deaths per year in the UK3 from an infection with multidrug-resistant bacteria and this is predicted to kill 10 million people every year globally by 2050, unless action is taken2
More info >>

White Papers

Using Device Strategy to Drive R&D Productivity


More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement